Special Issue "Noninvasive Early Disease Diagnosis"

A special issue of Biosensors (ISSN 2079-6374).

Deadline for manuscript submissions: 30 June 2019

Special Issue Editor

Guest Editor
Dr. A. Dan Wilson

Head Research Pathologist, USDA Forest Service R&D, Southern Hardwoods Laboratory, Southern Research Station, Stoneville, MS, 38776-0227 USA
Website | E-Mail
Phone: + 1 (662) 336 4809
Fax: + 1 (662) 336 4829
Interests: electronic noses; biomedical applications, clinical diagnostics; chemical sensors; noninvasive early disease detection, disease biomarker identification

Special Issue Information

Dear Colleagues,

This Special Issue of Biosensors focuses on recent sensors, biosensors, metabolomic instruments and associated methods developed for the noninvasive early detection and diagnosis of plant, animal, or human diseases. It celebrates over 30 years of sensor device developments for disease detection since electronic nose devices were first introduced in the mid-1980s. Since then, a wide range of sensor-system applications have been developed and applied to biomedical, clinical, and diagnostic applications. Among the key advantages of instruments that can detect complex mixtures of volatile organic compound (VOC) analytes in gaseous clinical samples are the capabilities of achieving noninvasive early disease detection before disease symptoms appear. The capability of simplifying and classifying complex chemical samples into simple sensory outputs make these devices unique among analytical instruments. These devices have the improved characteristics of simple operation, relatively low-cost, and real-time operation with high sample through-put.

For this Special Issue, we consider a wide range of sensor devices, designed for the common purpose of early disease detection, and developed for applications in laboratory, clinical, point-of-care testing, and scientific research situations. We are particularly interesting in receiving papers on recently developed novel instruments based on new approaches or technologies of early disease diagnostics that potentially improve on current or conventional diagnostic methods by yielding earlier and more accurate and reliable results that improve prognoses and reduce total healthcare costs.

Dr. A. Dan Wilson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 650 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Noninvasive early diagnosis
  • Clinical pathology
  • Electronic nose
  • Disease diagnostics
  • Point-of-care testing
  • Chemical sensors
  • Clinical pathology
  • Dysbiosis
  • Disease biomarkers
  • Metabolomics
  • Volatile organic compounds

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Breath Analysis Using eNose and Ion Mobility Technology to Diagnose Inflammatory Bowel Disease—A Pilot Study
Biosensors 2019, 9(2), 55; https://doi.org/10.3390/bios9020055
Received: 14 March 2019 / Revised: 29 March 2019 / Accepted: 8 April 2019 / Published: 12 April 2019
PDF Full-text (1025 KB)
Early diagnosis of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), remains a clinical challenge with current tests being invasive and costly. The analysis of volatile organic compounds (VOCs) in exhaled breath and biomarkers in stool (faecal calprotectin (FCP)) [...] Read more.
Early diagnosis of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), remains a clinical challenge with current tests being invasive and costly. The analysis of volatile organic compounds (VOCs) in exhaled breath and biomarkers in stool (faecal calprotectin (FCP)) show increasing potential as non-invasive diagnostic tools. The aim of this pilot study is to evaluate the efficacy of breath analysis and determine if FCP can be used as an additional non-invasive parameter to supplement breath results, for the diagnosis of IBD. Thirty-nine subjects were recruited (14 CD, 16 UC, 9 controls). Breath samples were analysed using an in-house built electronic nose (Wolf eNose) and commercial gas chromatograph–ion mobility spectrometer (G.A.S. BreathSpec GC-IMS). Both technologies could consistently separate IBD and controls [AUC ± 95%, sensitivity, specificity], eNose: [0.81, 0.67, 0.89]; GC-IMS: [0.93, 0.87, 0.89]. Furthermore, we could separate CD from UC, eNose: [0.88, 0.71, 0.88]; GC-IMS: [0.71, 0.86, 0.62]. Including FCP did not improve distinction between CD vs UC; eNose: [0.74, 1.00, 0.56], but rather, improved separation of CD vs controls and UC vs controls; eNose: [0.77, 0.55, 1.00] and [0.72, 0.89, 0.67] without FCP, [0.81, 0.73, 0.78] and [0.90, 1.00, 0.78] with FCP, respectively. These results confirm the utility of breath analysis to distinguish between IBD-related diagnostic groups. FCP does not add significant diagnostic value to breath analysis within this study. Full article
(This article belongs to the Special Issue Noninvasive Early Disease Diagnosis)

Graphical abstract

Biosensors EISSN 2079-6374 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top